Technologies

USF researchers have developed a compound capable of binding to sortilin. Specifically, the compound modulates distinctive sortilinligand interactions that are known to control proprotein convertase subtillisin/kexin type 9 (PCSK9) secretion. By inhibiting PCSK9 secretion, the novel formulation lowers low-density lipoprotein (LDL) cholesterol. Furthermore, this technique can also increase the amount of LDL receptors, subsequently minimizing the associated cardiovascular disease risks.

Researchers at the University of South Florida have developed novel compounds capable of binding to sortilin or related analogs to treat hypercholesteremia, hepatic steatosis, and Alzheimer's disease.